Skip to main content
. Author manuscript; available in PMC: 2022 Apr 22.
Published in final edited form as: J Med Chem. 2021 Mar 31;64(8):5099–5122. doi: 10.1021/acs.jmedchem.1c00164

Figure 4.

Figure 4.

Effects of P2Y14R antagonists and their prodrugs, compared to reference antagonist 1a, during allergen challenge reduce eosinophilic airway inflammation in the protease model of asthma. Effect on BALF leukocytes of i.p. injection of the P2Y14R antagonists 2 days post-challenge of ASP/OVA-sensitized mice. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 vs vehicle by one-way ANOVA followed by Dunnett’s test.